Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45 ET | BioNTech SE
Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use AuthorizationThe third 3-µg dose was well-tolerated among 1,678...
Pfizer-BioNTech COVID-19-Impfstoff zeigt bei Kindern im Alter von 6 Monaten bis unter 5 Jahren nach drei Dosen starke Immunantworten, hohe Wirksamkeit und vorteilhaftes Sicherheitsprofil
May 23, 2022 06:45 ET | BioNTech SE
Basierend auf den ersten Studiendaten erfüllen drei Dosen des Pfizer-BioNTech COVID-19-Impfstoffs alle für die US-Notfallzulassung notwendigen Immunobridging-Kriterien (Vergleich der...
ocugen_4C_LOGO (002).png
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
May 23, 2022 06:36 ET | Ocugen
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...
Picture3.png
California Organizations Partner to Hold 3rd Annual Town Hall Focused on Improving Health Outcomes for Black and Latinx Youth and Emerging Adults in and out of the Foster Care System
May 19, 2022 11:00 ET | Unity Care Group, Inc
SAN JOSE, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Unity Care, a San Jose-based nonprofit organization that provides safe, stable housing and supportive services for transition-age foster youth with...
Vice President Kamala Harris to Speak at the AAPI Victory Celebration Hosted by AAPI Victory Power Fund to Mobilize AAPI Electorate
May 19, 2022 10:16 ET | AAPI Victory Fund
WASHINGTON, May 19, 2022 (GLOBE NEWSWIRE) -- On Friday, May 20, 2022, at 6:15 p.m. ET/3:15 p.m. PT, AAPI Victory Power Fund will host the first-ever AAPI Victory Celebration, followed by the AAPI...
AIMLogo.jpg
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
May 19, 2022 08:00 ET | AIM ImmunoTech Inc.
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Diets, Food Prices, Stress and the Power of Gen Z Washington, D.C., May 18, 2022 (GLOBE NEWSWIRE) -- Major changes in Americans’ food attitudes and behaviors are emerging in the wake of the COVID-19 pandemic, according to the 2022 Food & Health...
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
May 18, 2022 08:00 ET | AIM ImmunoTech Inc.
OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial
May 17, 2022 15:48 ET | The Sabin Vaccine Institute
Washington, D.C., May 17, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute was awarded up to $6.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for a clinical trial to...
AIMLogo.jpg
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
May 12, 2022 08:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...